Comparative assessment of the absorption of a generic formulation of buprenorphine transdermal patch against the innovator buprenorphine transdermal patch conducted under fasting conditions and at steady state with the inclusion of a naltrexone block in healthy male and female volunteers
A multiple dose, randomized, open label, bioequivalence study of a test formulation of buprenorphine transdermal patch in a 2 way crossover comparison against the innovator buprenorphine transdermal patch conducted under fasting conditions and at steady state with the inclusion of a naltrexone block in healthy male and female volunteers
Zenith Technology Corp Ltd
32 participants
Jun 21, 2016
Interventional
Conditions
Summary
The objective of this study is to evaluate the bioequivalence of the test (new) formulation of 1 x 20 mcg/hr against the reference formulation (innovator brand of 1 x 20 mcg/hr buprenorphine transdermal patch) following oral administration of a multiple dose of 20 mcg/hr with the inclusion of a naltrexone block in healthy male and female subjects under fasting conditions and at steady state.
Eligibility
Inclusion Criteria6
- Healthy male and non-pregnant females
- Aged between 18 and 55
- Non-smoker
- BMI between 18.5 and 30 inclusive
- Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- Able to provide written informed consent
Exclusion Criteria10
- Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
- Concomitant drug therapy of any kind
- Sensitivity to buprenorphine or any other similar class of medicines, or the excipients of buprenorphine
- Sensitivity to naltrexone or any other similar class of medicines, or the excipients of naltrexone
- History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- Females who are pregnant and/or are breastfeeding
- Smoker (anyone who has smoked in the last 6 months)
- History of alcohol or drug abuse or dependency
- Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
- Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Multiple dose, crossover study design whereby each participant receives the test formulation of buprenorphine (1 x 20 mcg/hr patch) on three occasions with the patch being replaced every 7 days, and the innovator formulation of buprenorphine (1 x 20 mcg/hr patch) on three occasions with the patch being replaced every 7 days with the inclusion of a naltrexone block given 12 hours prior to patch application, at application and every 24 hours up until removal of the last patch in each study period. Each naltrexone dose will be 50 mg. Each buprenorphine dosing will be seperated by a four week washout period. The intervention for this trial is the test formulation of buprenorphine . Study Days 1 and 15 of each study period no water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose). Participants are required not to eat for 10 hours before receiving each dose on days 1 and 15 in each study period and to fast for approximately 4 hours after receiving each dose on days 1 and 15 of each study period. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 12 hours prior to dosing to ensure compliance and will be monitored and for 24 hours after dosing. Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 12 hours prior to dosing. On study days 2-14 and 16-22 subjects will report to Zenith Technology for the provision of one blood sample. Pre and post study laboratory tests will be completed to assess the health of participants along with HIV, Hepatitis and drugs of abuse testing. Each buprenorphine patch will be applied to the upper arm with each consecutive patch applied to a different site. Investigators will examine every subject to ensure the patch has been applied correctly. Each dose of naltrexone will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12616000600448